NRx Pharmaceuticals Statistics
Total Valuation
NRXP has a market cap or net worth of $143.63 million. The enterprise value is $117.78 million.
| Market Cap | 143.63M |
| Enterprise Value | 117.78M |
Important Dates
The last earnings date was Monday, August 17, 2026, before market open.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRXP has 43.26 million shares outstanding. The number of shares has increased by 110.42% in one year.
| Current Share Class | 43.26M |
| Shares Outstanding | 43.26M |
| Shares Change (YoY) | +110.42% |
| Shares Change (QoQ) | +16.47% |
| Owned by Insiders (%) | 4.12% |
| Owned by Institutions (%) | 21.53% |
| Float | 37.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42.32 |
| Forward PS | 3.06 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 34.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.86
| Current Ratio | 0.86 |
| Quick Ratio | 0.79 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -63.99% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -6,980.42% |
| Weighted Average Cost of Capital (WACC) | 16.81% |
| Revenue Per Employee | $117,034 |
| Profits Per Employee | -$809,655 |
| Employee Count | 29 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.70% in the last 52 weeks. The beta is 2.19, so NRXP's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +13.70% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 2.90 |
| Relative Strength Index (RSI) | 43.72 |
| Average Volume (20 Days) | 680,710 |
Short Selling Information
The latest short interest is 9.30 million, so 21.49% of the outstanding shares have been sold short.
| Short Interest | 9.30M |
| Short Previous Month | 8.67M |
| Short % of Shares Out | 21.49% |
| Short % of Float | 24.86% |
| Short Ratio (days to cover) | 8.11 |
Income Statement
In the last 12 months, NRXP had revenue of $3.39 million and -$23.48 million in losses. Loss per share was -$0.78.
| Revenue | 3.39M |
| Gross Profit | 1.58M |
| Operating Income | -19.96M |
| Pretax Income | -23.48M |
| Net Income | -23.48M |
| EBITDA | -19.76M |
| EBIT | -19.96M |
| Loss Per Share | -$0.78 |
Balance Sheet
The company has $26.69 million in cash and $834,000 in debt, with a net cash position of $25.85 million or $0.60 per share.
| Cash & Cash Equivalents | 26.69M |
| Total Debt | 834,000 |
| Net Cash | 25.85M |
| Net Cash Per Share | $0.60 |
| Equity (Book Value) | -170,000 |
| Book Value Per Share | -0.00 |
| Working Capital | -4.72M |
Cash Flow
In the last 12 months, operating cash flow was -$19.77 million and capital expenditures -$897,000, giving a free cash flow of -$20.67 million.
| Operating Cash Flow | -19.77M |
| Capital Expenditures | -897,000 |
| Depreciation & Amortization | 202,000 |
| Net Borrowing | 33,000 |
| Free Cash Flow | -20.67M |
| FCF Per Share | -$0.48 |
Margins
| Gross Margin | 46.64% |
| Operating Margin | -588.21% |
| Pretax Margin | -691.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -110.42% |
| Shareholder Yield | -110.42% |
| Earnings Yield | -16.35% |
| FCF Yield | -14.39% |
Analyst Forecast
The average price target for NRXP is $38.25, which is 1,052.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.25 |
| Price Target Difference | 1,052.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 668.69% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 2, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
NRXP has an Altman Z-Score of -13.93 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.93 |
| Piotroski F-Score | 2 |